Stephens Initiates Coverage on OptimizeRx (NASDAQ:OPRX)

Stephens started coverage on shares of OptimizeRx (NASDAQ:OPRX) in a research note published on Friday, Marketbeat Ratings reports. The firm issued an equal weight rating and a $5.50 price objective on the stock.

Other equities research analysts have also recently issued reports about the company. William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research note on Thursday, November 14th. JMP Securities reduced their target price on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 14th. Roth Mkm reissued a “buy” rating and set a $16.00 price target (down from $20.00) on shares of OptimizeRx in a research report on Thursday, November 14th. Barclays dropped their price objective on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 14th. Finally, Stifel Nicolaus decreased their target price on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.71.

OptimizeRx Stock Up 3.4 %

OPRX stock opened at $4.91 on Friday. OptimizeRx has a fifty-two week low of $3.78 and a fifty-two week high of $16.65. The company has a market capitalization of $90.45 million, a price-to-earnings ratio of -3.69 and a beta of 1.34. The business’s 50 day moving average price is $5.37 and its two-hundred day moving average price is $7.80. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23.

Insider Buying and Selling at OptimizeRx

In other OptimizeRx news, CEO William J. Febbo acquired 20,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $5.01 per share, with a total value of $100,200.00. Following the transaction, the chief executive officer now owns 601,253 shares of the company’s stock, valued at $3,012,277.53. The trade was a 3.44 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 6.10% of the stock is owned by company insiders.

Institutional Trading of OptimizeRx

A number of institutional investors and hedge funds have recently modified their holdings of the business. First Light Asset Management LLC boosted its position in shares of OptimizeRx by 5.1% during the second quarter. First Light Asset Management LLC now owns 1,826,961 shares of the company’s stock valued at $18,270,000 after buying an additional 89,377 shares during the last quarter. Rice Hall James & Associates LLC lifted its stake in OptimizeRx by 24.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock valued at $4,751,000 after acquiring an additional 119,306 shares during the period. Dimensional Fund Advisors LP lifted its stake in OptimizeRx by 12.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 324,130 shares of the company’s stock valued at $3,241,000 after acquiring an additional 35,957 shares during the period. Essex Investment Management Co. LLC boosted its holdings in shares of OptimizeRx by 42.9% during the 3rd quarter. Essex Investment Management Co. LLC now owns 242,025 shares of the company’s stock valued at $1,868,000 after acquiring an additional 72,672 shares during the last quarter. Finally, Bullseye Asset Management LLC grew its stake in shares of OptimizeRx by 55.6% in the third quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock worth $1,652,000 after acquiring an additional 76,458 shares during the period. Institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.